Verisante Technology this week announced several milestones in the development of its Raman spectroscopy-based cancer detection technology.

The company said that it has completed a clinical trial investigating the use of its Verisante Core device for the detection of lung cancer; launched a clinical study on use the Core for the detection of colon cancer; and entered a collaboration with the British Columbia Cancer Agency and China's Fujian Normal University to develop the Core device for detection of nasopharyngeal cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.